The effect of yttrium-90 implantation on endocrine function and visual fields in patients with "functionless" pituitary tumors, with biopsy and radiological findings.
Thirty patients with symptoms from "functionless" pituitary tumours were treated by yttrium-90 implants, and we report here the effects on symptoms, pituitary function and visual fields. On biopsy, about a third of the tumours showed some hormone granules. In the sixteen fully assessed at 1 year, pituitary function was improved in 25%, unchanged in 62-5%, and reduced in 12-5%. Improvement was confined to those in whom gonadotrophin secretion was the only function impaired pre-implant. Visual field defects were present pre-implant in ten patients (twenty eyes); at 1 year post-implant these defects had lessened in 80% and deteriorated in only 5% of eyes. Subsequently, within 5 years of the implant the field defects had worsened or recurred in four patients, all with initially extensive suprasellar projection; further treatment was then given. Remineralization of the sella was seen after implantation in seven cases, with reduction in fossa size in five. Thus pituitary implantation appears to be a practicable and reasonably simple procedure suitable for the treatment of most cases of "functionless" pituitary tumour. The "supressive" doses of irradiation used are adequate to shrink most tumours without loss of pituitary function.
D000236:Adenoma / Q000188:drug therapy; D000239:Adenoma, Acidophil / Q000473:pathology; D000238:Adenoma, Chromophobe / Q000473:pathology; D000293:Adolescent; D000328:Adult; D001706:Biopsy; D002784:Cholesterol / Q000097:blood; D005260:Female; D006056:Golgi Apparatus / Q000648:ultrastructure; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000627:therapeutic use; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008854:Microscopy, Electron; D008875:Middle Aged; D010901:Pituitary Function Tests; D010902:Pituitary Gland / Q000503:physiopathology*; D010910:Pituitary Irradiation; D010911:Pituitary Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011241:Prednisone / Q000627:therapeutic use; D011868:Radioisotopes / Q000627:therapeutic use*; D013972:Thyrotropin / Q000097:blood; D014056:Tomography, X-Ray; D014786:Vision Disorders / Q000628:therapy*; D014792:Visual Acuity; D014794:Visual Fields; D015019:Yttrium / Q000008:administration & dosage; D015020:Yttrium Isotopes / Q000627:therapeutic use*
D011868:Radioisotopes; D015020:Yttrium Isotopes; D015019:Yttrium; D007986:Luteinizing Hormone; D013972:Thyrotropin; D013006:Growth Hormone; D002784:Cholesterol; D011241:Prednisone; D006854:Hydrocortisone